RedHill Biopharma (RDHL) Receivables (2016 - 2025)

RedHill Biopharma (RDHL) has 10 years of Receivables data on file, last reported at $3.2 million in Q4 2025.

• On a quarterly basis, Receivables rose 26.59% year-over-year to $3.2 million in Q4 2025; TTM through Dec 2025 was $3.2 million, a 26.59% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, up 26.59% from the prior year.
• Receivables for Q4 2025 stood at $3.2 million, up from $2.5 million in the prior quarter.
• Over the last five years, Receivables for RDHL reached as high as $34.5 million in Q4 2022 and fell as low as $2.5 million in Q4 2024.
• Historically, Receivables has averaged $14.9 million across 5 years, with a median of $3.2 million in 2025.
• Across the five-year window, Receivables slumped 92.49% in 2023 and rose 26.59% in 2025, its largest moves.
• Year by year, Receivables stood at $31.7 million in 2021, then rose by 8.98% to $34.5 million in 2022, then slumped by 92.49% to $2.6 million in 2023, then slipped by 2.01% to $2.5 million in 2024, then rose by 26.59% to $3.2 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $3.2 million in Q4 2025, $2.5 million in Q4 2024, and $2.6 million in Q4 2023.